A Disease Registry of Patients With Mantle Cell Lymphoma
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 3 months and treatment is ongoing at the time of enrollment.
- Mantle Cell Lymphoma
- Eligible Ages
- Between 18 Years and 130 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Patient diagnosed with Mantle Cell Lymphoma (MCL) - Informed consent for participation - Age ≥ 18 years old, as of the first observed diagnosis of MCL - Patients for whom a clinical decision has been made to initiate novel therapy in the last 3 months, limited to the following novel agent categories: - Bcl-2 inhibitors - BTK inhibitors - Immunomodulatory agents - Phosphoinositide 3-kinase inhibitors The novel agent must have been granted approval in at least one haematological cancer. Treatment must be ongoing at the time of enrolment.
• Patient is participating in a clinical study that prohibits participation in non-interventional studies, or where treatment is blinded, at the time of consent.
- Study Type
- Observational Model
- Time Perspective
|Single cohort (registry) of MCL patients||Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 3 months and treatment is ongoing at the time of enrollment.|
Study ContactAstraZeneca Clinical Study Information Center
Newer targeted therapies (monotherapy or in combination with other agents) have been recently approved in the United States for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. The approval of these newer therapies will have an impact on the treatment patterns, toxicity patterns, and outcomes in the MCL population. A prospective, observational study will help to better understand the evolving real-world treatment outcomes (including treatment patterns, reasons for discontinuation/dose reduction, treatment interruption or treatment switches), physician-reported clinical outcomes, and patient-reported symptoms and health-related quality of life (HRQoL) among patients diagnosed with MCL who newly initiated a novel therapy in the past 3 months, and treatment is ongoing at the time of enrollment